The Endocannabinoid System and Physical Activity-A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders
- PMID: 35328503
- PMCID: PMC8948925
- DOI: 10.3390/ijms23063083
The Endocannabinoid System and Physical Activity-A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders
Abstract
Rapidly increasing worldwide prevalence of obesity and related pathologies encompassing coronary heart disease, hypertension, metabolic syndrome, or type 2 diabetes constitute serious threats to global health and are associated with a significantly elevated risk of premature death. Considering the enormous burden of these pathologies, novel therapeutic and preventive patterns are indispensable. Dysregulation of one of the most complex biological systems in the human body namely, the endocannabinoid system (ECS) may result in metabolic imbalance and development of insulin resistance, type 2 diabetes, or non-alcoholic fatty liver disease. Furthermore, many studies showed that physical exercises, depending on their type, intensity, and frequency, exert various alterations within the ECS. Emerging evidence suggests that targeting the ECS via physical activity may produce robust beneficial effects on the course of metabolic pathologies. However, the data showing a direct correlation between the ECS and physical activity in the aspect of metabolic health are very scarce. Therefore, the aim of this review was to provide the most up-to-date state of knowledge about the interplay between the ECS activity and physical exercises in the novel therapeutic and preventive approach toward metabolic pathologies. We believe that this paper, at least in part, will fulfill the existing gap in knowledge and encourage researchers to further explore this very complex yet interesting link between the ECS, its action in physical activity, and subsequent positive outcomes for metabolic health.
Keywords: 2-arachidonylglycerol; anandamide; cannabinoid receptor; endocannabinoid system; obesity; physical activity.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.Expert Opin Investig Drugs. 2012 Sep;21(9):1309-22. doi: 10.1517/13543784.2012.704019. Epub 2012 Jul 11. Expert Opin Investig Drugs. 2012. PMID: 22780328 Review.
-
Endocannabinoids and Metabolic Disorders.Handb Exp Pharmacol. 2015;231:367-91. doi: 10.1007/978-3-319-20825-1_13. Handb Exp Pharmacol. 2015. PMID: 26408168 Review.
-
Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.Physiol Behav. 2008 Mar 18;93(4-5):671-86. doi: 10.1016/j.physbeh.2007.11.012. Epub 2007 Nov 21. Physiol Behav. 2008. PMID: 18155257 Free PMC article. Review.
-
Peripheral modulation of the endocannabinoid system in metabolic disease.Drug Discov Today. 2018 Mar;23(3):592-604. doi: 10.1016/j.drudis.2018.01.029. Epub 2018 Jan 10. Drug Discov Today. 2018. PMID: 29331500 Review.
-
The Endocannabinoid System: Pivotal Orchestrator of Obesity and Metabolic Disease.Trends Endocrinol Metab. 2015 Oct;26(10):524-537. doi: 10.1016/j.tem.2015.07.007. Trends Endocrinol Metab. 2015. PMID: 26412154 Review.
Cited by
-
Beta-Caryophyllene Modifies Intracellular Lipid Composition in a Cell Model of Hepatic Steatosis by Acting through CB2 and PPAR Receptors.Int J Mol Sci. 2023 Mar 23;24(7):6060. doi: 10.3390/ijms24076060. Int J Mol Sci. 2023. PMID: 37047034 Free PMC article.
-
Sex differences in endocannabinoids during 3 years of Mediterranean diet intervention: Association with insulin resistance and weight loss in a population with metabolic syndrome.Front Nutr. 2022 Dec 1;9:1076677. doi: 10.3389/fnut.2022.1076677. eCollection 2022. Front Nutr. 2022. PMID: 36532543 Free PMC article.
-
Effects of five cannabis oils with different CBD: THC ratios and terpenes on hypertension, dyslipidemia, hepatic steatosis, oxidative stress, and CB1 receptor in an experimental model.J Cannabis Res. 2025 Jul 14;7(1):46. doi: 10.1186/s42238-025-00286-8. J Cannabis Res. 2025. PMID: 40660358 Free PMC article.
-
The role of tetrahydrocannabivarin (THCV) in metabolic disorders: A promising cannabinoid for diabetes and weight management.AIMS Neurosci. 2025 Mar 12;12(1):32-43. doi: 10.3934/Neuroscience.2025003. eCollection 2025. AIMS Neurosci. 2025. PMID: 40270953 Free PMC article. Review.
-
The Endocannabinoid System and Physical Exercise.Int J Mol Sci. 2023 Jan 19;24(3):1989. doi: 10.3390/ijms24031989. Int J Mol Sci. 2023. PMID: 36768332 Free PMC article. Review.
References
-
- Mayoral L.P.-C., Andrade G.B., Mayoral E.P.-C., Teresa H.H., Socorro P.C., Francisco J.R.C., Héctor A.C.-F., Cruz M.M., Santiago A.D.P., Alpuche J.J., et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J. Med. Res. 2020;151:11–21. doi: 10.4103/ijmr.IJMR_1768_17. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous